ClinicalTrials.gg
RecruitingNCT06355258Updated Nov 12, 2024

A Study of the Efficacy of Troxerutin in Preventing Thrombotic Events in COVID-19 Patients

A Phase 1 interventional study of Troxerutin and Placebo in COVID 19 Associated Coagulopathy, sponsored by Westlake University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-12.

Sponsored by Westlake University · Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Dec 2023, registered Apr 2024).
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 472 studies in COVID-19 with a site in China — 53 open to participants now, 75 under way, 8 of them phase 3. COVID-19 · China.

Planned enrollment
224th of 330
80 · median 200
Started
2023
with 103 others
Phase 1
67 of 472
7 open now
Primary completion
2024-12
later than 49 of 74 live
Registered
451st of 472
by date

Among the 472 studies in COVID-19 with a site in China, this one is the 224th largest by planned enrollment of the 330 interventional ones that give a count, is one of 104 that started in 2023, is one of 67 in phase 1, reaches primary completion later than 49 of the 74 other live ones, and was the 451st registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

53 of the 472 studies in COVID-19 with a site in China are open now. Recruiting first, the newest first:

47 more — sign in →

All 53 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 472 studies in COVID-19 with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if troxerutin works to prevent thrombotic events in mild or severe COVID-19 patients. It will also learn about the safety of troxerutin. The main questions it aims to answer are:

  • Does troxerutin lower the number of thrombotic events in participants?
  • What medical problems do participants have when taking troxerutin? Researchers will compare troxerutin to a placebo (a look-alike substance that contains no drug) to see if troxerutin works to prevent thrombotic events in COVID-19 patients.

Participants will:

  • Take troxerutin or a placebo every day for 7 days.
  • Visit the clinic at the first, fourth, seventh and 28th days after enrollment for checkups and tests
  • Keep a diary of their symptoms and the number of times of thrombotic events, bleeding events and type II HIT-related thrombocytopenia
03

Conditions studied

  • COVID 19 Associated Coagulopathy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

As long as the patient meets all of the following conditions, adult patients aged 18 and above are eligible for admission:

► COVID-19 patients, defined as: positive RT-PCR (upper respiratory tract or lower respiratory tract) for SARS-CoV-2.

Mild COVID-19 patients are defined as:

Symptomatic patients meeting the case definition for COVID-19 without evidence of hypoxia or pneumonia. Common symptoms include fever, cough, fatigue, anorexia, dyspnea, and myalgia. Other nonspecific symptoms include sore throat, nasal congestion, headache, diarrhea, nausea/vomiting, and loss of smell/taste.

Severe COVID-19 patients are defined as:

Adolescents or adults with clinical signs of pneumonia (i.e., fever, cough, dyspnea, tachypnea) plus one of the following:

  1. Respiratory rate ≥30 breaths/min
  2. Severe respiratory distress
  3. Oxygen saturation (SpO₂) ≤90% in room air
  4. Progressive deterioration of clinical symptoms with lung imaging showing significant progression of lesions (>50%) within 24 to 48 hours.

    • Written provided according to Chinese law (by the patient, legal guardian, or deferred consent in emergencies).

Exclusion criteria

Exclusion Criteria:

Patients with any of the following conditions will be excluded from the study:

  • Pregnant or lactating women.
  • Postpartum (within 6 weeks).
  • Extreme weight (100 kilograms).
  • Clinical need for heparin therapy.
  • Bleeding related to coagulation disorders, acute bleeding, active gastrointestinal ulcers, or any organic lesions with high bleeding risk.
  • count \<50 x 10\^9/L.
  • Surgery within the last 15 days, or within 24 hours after spinal or epidural anesthesia.
  • History of intracranial hemorrhage, large ischemic stroke, known intracranial malformation or tumor, acute infective endocarditis.
  • Severe renal impairment ( \<30 mL/min).
  • Iodine allergy.
  • Long-term use of oxygen supplementation.
  • Moribund patients or those expected to die during the current hospitalization due to underlying disease.
  • Patients deprived of freedom and those undergoing institutional psychiatric care.
  • Ward of the state or under guardianship.
  • Participation in other anticoagulant intervention studies.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Troxerutin+low molecular weight heparin

    Drug: troxerutin + low molecular weight heparin

  • Placebo comparator
    Placebo+low molecular weight heparin

    Drug: placebo + low molecular weight heparin

  • Experimental
    Troxerutin

    Drug: Troxerutin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugTroxerutin

    Oral troxerutin tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily

  • DrugPlacebo

    Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily

  • Drugplacebo + low molecular weight heparin

    2000 IU LMWH once a day + Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily

  • Drugtroxerutin + low molecular weight heparin

    Drug page: Heparin, Low-Molecular-WeightStudies of Heparin, Low-Molecular-WeightHeparin, Low-Molecular-Weight pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    2000 IU LMWH once a day + Oral troxerutin tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily

06

What researchers measure

Primary outcomes

  1. Overall number of patients in prothrombotic state through 7 days

    Assess coagulation-related parameters in patients' blood, including platelet count, prothrombin time (PT), antithrombin III activity (ATIIIa), plasma fibrinogen concentration (Fbg), and quantitative D-dimer.Patients with one or more indicators in the abnormal range, including PT \< 11s (reference interval: 11-14 s), FG \> 4g/L (reference interval: 2-4 g/L), D-dimer \< 0.5 μg/mL (reference interval: 0-0.5 μg/mL), are considered in a prothrombotic state.

    Time frame: Through 7 days

Secondary outcomes

  1. Tolerability of anticoagulation therapy

    Percentage of patients experiencing at least one major bleeding event (MBE) as defined by the International Society on Thrombosis and Haemostasis (ISTH) by day 28.

    Time frame: Through 28 days

  2. Adverse event

    Percentage of patients experiencing at least one adverse event above grade 2

    Time frame: Through 28 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2024, 12 months after the start.

Of 151 non-industry phase 1 interventional studies under COVID-19, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's planned 12 months is close to that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2024
First posted
Apr 9, 2024
StartActual
Dec 15, 2023
Primary completionEst.
Dec 2024
CompletionEst.
Mar 2025
Last update
Nov 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06355258
Lead sponsor
Westlake University
Collaborators
Shaoxing Central Hospital, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
Responsible party
Sponsor
First posted
Apr 9, 2024
Start date
Dec 15, 2023
Primary completion
Dec 2024 (estimated)
Completion
Mar 2025 (estimated)
Last update
Nov 12, 2024

Study contacts

Xu Li, PhD
Contact
lixu@westlake.edu.cn
13811635032

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Heparin, Low-Molecular-Weight

Start the discussion